Inhaled allergen is an important cause of asthma in clinical practice. In the laboratory, allergen inhalation tests are a useful tool for investigating allergen-induced asthmatic responses. Allergen inhalation causes airway narrowing, usually within 15 min, in sensitized subjects. This early asthmatic response resolves within 2–3 h. In 50% of adult subjects exposed to allergen, a late bronchoconstrictor response, which begins 3–4 h after allergen inhalation, also occurs [1]. The late asthmatic response is more prolonged than the early response and is associated with airway hyperresponsiveness to bronchoconstrictor stimuli such as histamine or methacholine [2], which can last for days or weeks following allergen exposure [3].

The precise mechanisms for the development of the airway responses following inhaled allergen are unclear. The early asthmatic response is believed to occur because of the release of bronchoconstrictor mediators such as histamine [4], the sulphidopeptide leukotrienes [5, 6] and thromboxane [7, 8]. The late response and subsequent airway hyperresponsiveness is associated with an acute inflammatory response, as measured by the influx of inflammatory cells, such as eosinophils [9], into the airways.

Thromboxane may also be involved in the pathogenesis of airway hyperresponsiveness after allergen inhalation. Studies in dogs have demonstrated that pretreatment with a thromboxane synthetase inhibitor, OKY 046, prevents the development of airway hyperresponsiveness after allergen inhalation [10]. OKY 046 also prevents the development of airway hyperresponsiveness following inhaled leukotriene B4 [11] and ozone exposure [12] in dogs. In addition, indomethacin, an inhibitor of cyclooxygenase and therefore of thromboxane and prostaglandin synthesis, inhibits the development of airway hyperresponsiveness following allergen in allergic sheep [13] and in human subjects [14].

The purpose of this study was to evaluate the possible role of thromboxane in causing allergen-induced asthmatic responses. This was done by examining the effects of a specific thromboxane synthetase inhibitor, CGS 13080 (imidazo [1, 5–2] pyridine-5-hexanoic acid) [15], on levels of serum thromboxane B2 (TxB2), which
is the spontaneous hydrolytic product of thromboxane
A\textsubscript{2} and on the development of asthmatic responses after
inhaled allergen.

**Methods**

**Subjects**

Twelve subjects were studied in the clinical research
laboratories of McMaster University Medical Center,
Hamilton and Section of Respiratory Medicine, University
Hospital, Saskatoon, Canada (table 1). All the
subjects had a history of current or previous asthma,
and all had previously documented early and late
asthmatic responses and increased airway responsiveness
following exposure to inhaled allergen. The baseline
forced expired volume in 1 s (FEV\textsubscript{1}) was >75%
predicted normal [16] in all subjects on all study days
(table 1). All the subjects were atopic, as determined
by 1 or more positive responses to skin prick tests with
16 common allergens. The subjects with current or
seasonal asthma were studied when their asthma was
mild and controlled by inhaled \( \beta \)-agonists alone, with
no exacerbations of asthma for at least four weeks. There
was no current exposure to allergens to which subjects
were sensitized, except for house dust mite. The study
was approved by each hospital’s Ethics Committee and
subjects gave written informed consent before begin­
in the study.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age</th>
<th>Sex</th>
<th>Allergen</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>46</td>
<td>F</td>
<td>D. Farinae</td>
<td>S not daily</td>
</tr>
<tr>
<td>2</td>
<td>36</td>
<td>M</td>
<td>D. Farinae</td>
<td>S not daily</td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>F</td>
<td>D. Farinae</td>
<td>S not daily</td>
</tr>
<tr>
<td>4</td>
<td>23</td>
<td>F</td>
<td>D. Farinae</td>
<td>S not daily</td>
</tr>
<tr>
<td>5</td>
<td>37</td>
<td>F</td>
<td>D. Farinae</td>
<td>nil</td>
</tr>
<tr>
<td>6</td>
<td>23</td>
<td>M</td>
<td>D. Farinae</td>
<td>nil</td>
</tr>
<tr>
<td>7</td>
<td>25</td>
<td>F</td>
<td>Ragweed</td>
<td>S not daily</td>
</tr>
<tr>
<td>8</td>
<td>23</td>
<td>M</td>
<td>Ragweed</td>
<td>nil</td>
</tr>
<tr>
<td>9</td>
<td>25</td>
<td>F</td>
<td>Cat dander</td>
<td>S not daily</td>
</tr>
<tr>
<td>10</td>
<td>30</td>
<td>M</td>
<td>Cat dander</td>
<td>S not daily</td>
</tr>
<tr>
<td>11</td>
<td>42</td>
<td>M</td>
<td>Grass pollen</td>
<td>S not daily</td>
</tr>
<tr>
<td>12</td>
<td>21</td>
<td>M</td>
<td>Tree pollen</td>
<td>nil</td>
</tr>
</tbody>
</table>

S: Salbutamol

**Study Design**

Subjects attended the laboratory on 9 study days
divided into three periods. In the first period, subject
characteristics were documented and a diluent inhalation
test with saline was performed. The second and
third study periods were similar to the saline day except
that allergen replaced saline as the inhalation test. In
addition, two histamine inhalation tests were carried out,
the initial one on the day prior to and the second one on
the day after the allergen test in order to document the
change in airway responsiveness following allergen
exposure.

During the second and third study periods, subjects
were pretreated with either the thromboxane synthetase
inhibitor CGS 13080 200 mg or placebo administered
orally four times daily for two days before, the day of,
and the day after allergen inhalation. The allergen
inhalation tests were carried out 1 h following a dose of
medication. The study was double-blinded, randomized,
with a crossover design.

The response to inhaled allergen is determined, in
part, by the level of airway responsiveness, therefore
each study period was started only when airway
responsiveness to histamine had returned to within a
single doubling concentration of the initial baseline
value. Inhaled \( \beta \)-agonists were withheld for at least
8 h before either the histamine or the allergen inhalation
tests.

**Histamine inhalation tests**

This test was carried out by the method of COCKCROFT
et al. [17] using a Wright nebulizer with an output of
0.13 ml·min\textsuperscript{-1}. After nebulization of saline, increasing
doubling concentrations of histamine phosphate were
inhaled until a 20% fall in FEV\textsubscript{1} was obtained.
Dose-response curves were drawn on a semilogarithmic
non-cumulative scale. The concentration causing a 20%
fall in FEV\textsubscript{1} (PC\textsubscript{20}) was interpolated from the individual
dose response curves.

**Allergen Inhalation Tests**

Allergen inhalation tests were performed as previously
described [1] using a Wright nebulizer with an output of
0.13 ml·min\textsuperscript{-1}. The nose was clipped and aerosols
were inhaled through a mouth piece during tidal
breathing. The starting concentration of inhaled allergen
extract was determined from prick tests with the same
extract and the histamine PC\textsubscript{20} in the entry period, using
the formula described by COCKCROFT et al. [18]. This
starting concentration was two doubling concentrations
below that predicted to cause a 20% fall in FEV\textsubscript{1}.
Doubling concentrations of allergen were inhaled for 2
min and the FEV\textsubscript{1} was measured 10 min after each
inhalation. If the FEV\textsubscript{1} had fallen by 15% or more, the
FEV\textsubscript{1} was repeated at 10 minute intervals until no further
fall in FEV\textsubscript{1} was observed. The FEV\textsubscript{1} was then
measured at 20, 30, 45, 60, 90 and 120 min and then at
hourly intervals until 7 h after the inhalation.

The house dust mite, tree and grass pollen allergen
efacts were obtained from Miles/Hollister-Stier,
Mississauga, Ontario and the ragweed and cat dander
efacts were obtained from Dr. Jerry Dolovich,
Hamilton, Ontario. Extracts were stored at \(-70^\circ\text{C}\) and
diluted for skin tests and allergen inhalation on the day of
use.

**Diluent Inhalation Tests**

Diluent inhalation tests were performed in a similar
manner to the allergen and the same Wright nebulizer
was used. Subjects inhaled diluent (phosphate buffered
saline with 1.5% benzyl alcohol) for 2 min on 3 occasions 10 min apart. Each inhalation was followed by measurements of FEV₁ using the same schedule followed during the allergen inhalation tests.

 Serum Thromboxane B₂ measurements

Five ml of blood was collected in a glass tube containing no anticoagulant. Four samples were obtained on each study day, just prior to and at 3, 7 and 24 h following the saline or allergen inhalation tests. The blood samples were incubated in a water bath for 1 h at 37°C. The samples were then centrifuged at 2000 g for 15 min to separate serum from the clot. The serum was then aspirated into a polypropylene tube and frozen at -70°C until analysis using the radioimmunoassay method as previously described [15]. The radioimmunoassays were performed blinded by Ciba-Geigy, New Jersey.

Analysis

The effect of CGS 13080 was compared with placebo on the levels of serum TxB₂, baseline airway calibre as measured by FEV₁, histamine airway responsiveness, allergen-induced early and late asthmatic responses and allergen-induced increases in histamine airway responsiveness.

All analysis of the histamine PC₂₀'s were performed on log transformed data and therefore summary statistics are expressed as geometric mean and percent standard error of the mean (%SEM). All other summary statistics are expressed as mean and standard error of the mean. The bronchoconstrictor responses during the early (0–1 h) and late (3–7 h) asthmatic responses, and the serum thromboxane B₂ levels on the saline, placebo and CGS 13080 study days were compared using two way ANOVA.

The comparison of the log difference (the arithmetic ratio) of histamine PC₂₀ before and 24 h after allergen in both study periods is the appropriate assessment of placebo and CGS 13080 pretreatment on changes in airway responsiveness after allergen. A log difference of 0 signifies no change in airway responsiveness. The effect of CGS 13080 and placebo on baseline histamine responsiveness and on the increases in histamine responsiveness after allergen were compared using two-tailed Student t-tests for paired observations. Statistical significance was accepted at the 95% level.

Results

Treatment with the thromboxane synthetase inhibitor, CGS 13080 had a small but statistically significant effect on the magnitude of the early asthmatic responses after inhaled allergen (fig. 1). There was significantly less bronchoconstriction at all time points up to 1 h after allergen during CGS 13080 treatment when compared to the bronchoconstriction after allergen during placebo treatment (p=0.0009). The mean maximal early fall in FEV₁ during the first hour after allergen during placebo treatment was 27% (SEM 3.9%) compared to 21% (SEM 3.3%) after allergen during CGS 13080 treatment.

CGS treatment did not alter the late asthmatic response, baseline FEV₁, baseline histamine airway responsiveness, or the increase in histamine airway responsiveness after inhaled allergen. There was no significant difference in the bronchoconstriction at all time points between 3–7 h following allergen after CGS 13080 treatment when compared to the bronchoconstriction following allergen after placebo (p=0.95) (fig. 1). The mean maximal late fall in FEV₁ between 3–7 h after placebo was 28% (SEM 4.7%) and after CGS 13080 was 29% (SEM 4.6%). The mean baseline FEV₁ values before and after 2 days of CGS 13080 were 3.26 l (SEM 0.23) and 3.32 l (SEM 0.23) (p=0.73). The mean histamine PC₂₀ during the placebo period was 3.22 mg·ml⁻¹ (SEM 1.36) and during the CGS 13080 period was 2.64 mg·ml⁻¹ (SEM 1.31) (p=0.33). Following allergen inhalation during the placebo period the mean histamine PC₂₀ decreased to 1.25 mg·ml⁻¹ (SEM 1.37) (p<0.0001) and during the CGS 13080 period decreased to 1.11 mg·ml⁻¹ (SEM 1.32) (p=0.063) (fig. 2). The mean log difference of the histamine PC₂₀ pre-post allergen was 0.41 (SEM 0.06) during the placebo period and 0.38 (SEM 0.10) during CGS 13080 treatment (p=0.73).

On placebo treatment, a small, but not statistically significant, increase in serum TxB₂ levels occurred 3 h after allergen inhalation when compared to the pre-allergen baseline levels (p=0.07); however, when

Fig. 1. – The mean fall in forced expiratory volume in one second (FEV₁) after inhaled diluent (solid circles) and during the early and late asthmatic response after inhaled allergen after placebo (open squares) and CGS 13080 (closed squares) pretreatment. CGS 13080 had a small but statistically significant effect on the magnitude of the early but not the late asthmatic responses.
compared to the levels at 3 h after the diluent inhalation, the increase was significant. The mean levels were 151 ng·ml\(^{-1}\) (SEM 27.4) 3 h after allergen compared to 96 ng·ml\(^{-1}\) (SEM 28.4) 3 h after diluent (p=0.008) (fig. 3).

At 7 h, the TxB\(_2\) levels were again slightly, but not significantly, increased after allergen at 130 ng·ml\(^{-1}\) (SEM 30.5) compared to 85 ng·ml\(^{-1}\) (SEM 21.0) after diluent at the same time point (p=0.10). No other significant differences in serum TxB\(_2\) levels were demonstrated either at baseline or at the other time points following allergen exposure during the placebo period (fig. 3).

CGS 13080 significantly inhibited the baseline TxB\(_2\) levels and the levels at all time points after inhaled allergen (fig. 3). The mean TxB\(_2\) levels during CGS 13080 treatment, 3 h after allergen, were 25 ng·ml\(^{-1}\) (SEM 10.2), which was significantly different to the values 3 h after allergen during placebo treatment (p=0.0001).

**Discussion**

This study has demonstrated that serum TxB\(_2\) levels increase following the early asthmatic response to inhaled allergen in subjects with mild asthma. These increases in thromboxane are prevented by treatment with CGS 13080, a thromboxane synthetase inhibitor, which also partially inhibits the early asthmatic response. CGS 13080 did not however influence either the late asthmatic response or the airway hyperresponsiveness following allergen stimulation. These results suggest that thromboxane is in part responsible for the bronchoconstriction which occurs during the early response after inhaled allergen but is not responsible for the late asthmatic response or the airway hyperresponsiveness after inhaled allergen.

TxA\(_2\) has a short half-life of approximately 30 s. In this study, we measured serum TxB\(_2\), which is the spontaneous hydrolytic product of TxA\(_2\), before, during and after the allergic responses mainly to evaluate patient compliance in taking the study drug, which should reduce serum TxB\(_2\) levels [15], and to ensure the inhibition of thromboxane synthesis persisted during all of the physiologic measurements. To this end, the measurements of serum TxB\(_2\) after allergen were made at 3 h, 7 h and at 24 h. The finding of increased serum TxB\(_2\) levels following the early asthmatic response confirms observations of Shephard et al. [19], who demonstrated increased plasma TxB\(_2\) levels after allergen inhalation in asthmatic subjects, with peak levels between 45 min to 2 h after allergen. It is likely, therefore, that we missed the peak increases in serum TxB\(_2\) after allergen inhalation in this study. Despite this, a significant increase was demonstrated after the early response at 3 h, when compared to the levels measured after diluent inhalation. The comparison between the serum TxB\(_2\) levels measured after allergen inhalation and diluent inhalation was made to ensure the levels were measured at the same time of day and after a similar number of forced expiration manoeuvres. These results support other studies which have indicated that serum TxB\(_2\) is increased after allergen inhalation [19]. However, it is likely that these levels reflect the capacity of platelets to release thromboxane ex vivo [20], rather than thromboxane release in the lungs as part of an allergic response. Thus the increased serum TxB\(_2\)
levels after allergen inhalation may be a marker of platelet activation, which has been described after allergen inhalation [21].

CGS 13080, the thromboxane synthetase inhibitor used in this study, is highly selective and potent in human subjects [15, 22], with 99% maximal inhibition of thromboxane production with lower doses than were used in the current study [15]. Consistent with this evidence, CGS 13080 treatment effectively inhibited both the pre-allergen basal serum levels of TxB₂ and also the rise in serum TxB₂ after inhaled allergen in this study. The extent of the inhibition (approximately 80%) was less than previously reported with this inhibitor [15]; however, inhibition occurred in all subjects through the active treatment period, indicating compliance with the study medication. CGS 13080 treatment also partially inhibited the magnitude of the early bronchoconstrictor response to allergen (mean 22% inhibition), presumably due to inhibition of thromboxane release. However, there is evidence that during thromboxane synthetase inhibition, endoperoxides are shunted into the production of prostacyclin [15, 22] and prostaglandin E₂ [15]. Therefore, the inhibition of the early asthmatic response could occur through production of these inhibitory prostanooids. However, BEASLEY et al. [7] showed a similar degree of inhibition (mean 23.6%) of the early asthmatic response to inhaled allergen following treatment with a thromboxane receptor antagonist. This thromboxane antagonist would not cause shunting of endoperoxides. The results of these studies support a role for thromboxane playing a small role in the bronchoconstriction which occurs during the first hour after inhaled allergen. Clearly, other bronchoconstrictor mediators, for example the sulphidopeptide leukotrienes [5, 6], are playing a much greater part in causing this response.

Thromboxane does not appear to be important in causing the physiologic manifestations of the late asthmatic response or airway hyperresponsiveness after allergen. We could not demonstrate a significant increase in serum thromboxane during the late asthmatic response, which is consistent with the findings of SHEPHARD et al. [8]. Also, CGS 13080 did not influence the magnitude of the late response. An important role for thromboxane in the pathogenesis of allergen-induced airway hyperresponsiveness has been suggested by studies which have demonstrated in dogs that OKY 046, a thromboxane-synthetase inhibitor, prevents allergen-induced airway hyperresponsiveness [10]. In addition, OKY 046 also prevents ozone [12], platelet activating factor [23] and leukotriene B₄-induced airway hyperresponsiveness [11]. Also, the cyclooxygenase-inhibitor, indomethacin, inhibits the development of allergen-induced airway hyperresponsiveness in sheep [13] and humans [14], which has suggested that a cyclooxygenase product of arachidonate metabolism is involved. The current study suggests that thromboxane is not the cyclooxygenase product involved in causing allergen-induced airway hyperresponsiveness.

Indomethacin is a potent inhibitor of cyclooxygenase and therefore inhibits thromboxane production. However, neither we [14], nor others [8, 24], have been able to demonstrate inhibition of the early asthmatic response in asthmatic subjects by indomethacin pretreatment. These results suggest that either indomethacin is not an effective inhibitor of thromboxane production in the lungs, or that the bronchoconstriction after inhaled allergen is both stimulated and inhibited by different cyclooxygenase products, or that indomethacin allows shunting of arachidonate into the production of the bronchoconstrictor sulphidopeptide leukotrienes. Support for the latter hypothesis comes from studies by Fisht al. [24], who demonstrated that indomethacin enhanced the bronchoconstrictor responses to inhaled allergen in nonasthmatic, atopic subjects, which suggests that indomethacin can promote the production of bronchoconstrictor mediators after allergen. Also, in sheep, treatment with indomethacin enhances the production of leukotrienes [25]; however these same investigators could not find evidence for this effect of cyclooxygenase inhibition after allergen challenge in human subjects [26].

CGS 13080 pretreatment administered orally did not inhibit baseline airway calibre, as measured by the FEV₁, or baseline pre-allergen histamine airway responsiveness. This suggests that thromboxane is not an important mediator in controlling baseline airway function. These results differ from those of FUMURA et al. [27], who demonstrated a significant reduction in acetylcholine airway responsiveness following oral treatment with the thromboxane synthetase inhibitor, OKY 046. The reason for these differences is not clear but may be due to differences in the pharmacological profile of the drugs used, in the subjects studied, or in the fact that different bronchoconstrictor agonists were used.

In summary, the results from this study suggest that thromboxane is, in part, responsible for the early but not the late asthmatic responses nor the airway hyperresponsiveness after inhaled allergen in asthmatic subjects.

Acknowledgements: We gratefully acknowledge J. Otis for her careful preparation of the figures, G.L. Jones for statistical help, and Ciba-Geigy, Inc. for their support of the study.

References


**RÉSUMÉ:** Dans cette étude, nous avons évalué le rôle du thromboxane dans les réponses asthmatiques précoces et tardives induites par les allergènes, et dans l’hyperréactivité bronchique des sujets asthmatiques. Douze sujets atopiques avec un asthme stable et des réponses précoces et tardives documentées à un allergène inhalé, ont été traités par un placebo ou par le CGS 13080, un inhibiteur spécifique du thromboxane synthétase, administré par voie orale à raison de 200 mg 4 fois par jour au cours des deux journées précédant l’inhalaion d’allergène, le jour de cette provocation, et le jour suivant. Les traitements ont été administrés avec perméation croisée au cours d’un essai en double aveugle contrôlé par placebo. L’effet du traitement au CGS 13080 a été examiné à la fois sur les niveaux de l’anti-thromboxane B₂, sériques et intraplacentaires, ainsi que sur l’amplitude des réactions asthmatiques après inhalation de l’allergène. Les niveaux de l’anti-thromboxane B₂ ont été augmentés significativement de 96 ng/ml (seuils 29) 3 heures après l’inhalaion de l’agent diluant, jusqu’à 151 ng/ml (seuils 27) 3 heures après l’inhalaion de l’allergène (p=0.008). Un traitement pré-voie au moyen de CGS 13080 a inhibé considérablement les niveaux de l’anti-thromboxane B₂, à tous les moments avant et après l’inhalaion de l’allergène (p=0.0001) et a eu un effet léger sur l’amplitude des réactions asthmatiques précoces après allergène (p=0.0009). CGS 13080 n’a pas altéré ni la réactivité asthmatique, ni la réactivité bronchique de base, ni l’inhibition de la réactivité des voies aériennes à l’histamine après provocation allergénique. Ces résultats suggèrent que les réactions asthmatiques précoces induites par les allergènes, mais non les réactions tardives ou l’hyperréactivité d’origine allergénique, sont partiellement causées par la libération de thromboxane. *Eur Respir J.*, 1991, 4, 667–672.